A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 – Vienna, Austria).

• Autores: Xavier Rabasseda
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 51, Nº. 4, 2015, págs. 261-271
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • While Vienna's Prater park offers a varied selection of options, from theme parks to lush gardens and prairies to enjoy the sun, the nearby Messe Wien convention center was the focus of attention in April 2015 for all the scientists, researchers and clinicians interested in viral hepatitis, nonalcoholic steatohepatitis, hepatocellular carcinoma and a variety of other liver diseases. Treatments and potential new therapeutic strategies for these hepatopathies were discussed during the 50th International Liver Congress organized by the European Association for the Study of the Liver. Echoing epidemiological facts and a high social interest for hepatitis C virus infection, new findings with investigational and potential new therapies for the disease centered much of the attention at the conference. Nevertheless, new research was also reported related to potential improvements in how other liver diseases, particularly hepatitis B virus infection, hepatocellular carcinoma and a range of inflammatory and immune-mediated liver diseases, including rare hereditary diseases that should never be forgotten.